劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02595 劲方医药-B

休市中 11-06 16:08:52

21.800

-1.980

-8.33%

最高23.240	最低21.660	成交量197.94万
今开23.240	昨收23.780	日振幅6.64%
总市值83.06亿	流通市值76.08亿	总股本3.81亿
成交额4,413万	换手率0.57%	流通股本3.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":21.8,"timestamp":1793952532008,"preClose":23.78,"halted":0,"volume":1979400,"delay":0,"changeRate":-0.08326324642556772,"floatShares":349000000,"shares":381000000,"eps":-6.07,"marketStatus":"休市中","change":-1.98,"latestTime":"11-06 16:08:52","open":23.24,"high":23.24,"low":21.66,"amount":44133172,"amplitude":0.066442,"askPrice":21.86,"askSize":1400,"bidPrice":21.8,"bidSize":21600,"shortable":3,"etf":0,"ttmEps":-3.968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":7,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":23.78,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.3558521681538191,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02595","defaultTab":"news","newsList":[{"id":"1162860312","title":"异动解读｜劲方医药-B盘中下跌6.14%，前日大涨后短线回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1162860312","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162860312?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:41","pubTimestamp":1793929267,"startTime":"0","endTime":"0","summary":"11月6日，劲方医药-B盘中下跌6.14%，报22.88港元，成交额521.72万港元。就近消息看，公司此前上涨主要受GFH276多项创新联合疗法获临床试验许可、基金增持至5.05%及持续回购带动；但本次异动时点暂无新增催化落地，股价在前一交易日快速冲高后出现回吐。已披露信息显示，10月30日有机构场内增持29.96万股，均价23.4445港元，持股比例升至5.05%；公司10月内累计回购114.88万股并持作库存股份。此前利好已被市场交易后，短线波动加大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"劲方医药短线回吐，创新药利好消化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681602935","title":"东方证券股份有限公司(DFZQ)增持劲方医药-B(02595.HK)29.96万股 每股作价约23.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681602935","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681602935?lang=zh_cn&edition=full","pubTime":"2026-11-05 19:25","pubTimestamp":1793877919,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03958","BK1574","BK1147","BK1564","09939","BK1161","02595","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157967628","title":"劲方医药-B：东方证券股份有限公司（DFZQ）增持，好仓比例升至5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157967628","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157967628?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:22","pubTimestamp":1793870565,"startTime":"0","endTime":"0","summary":"东方证券股份有限公司（DFZQ）于2026年10月30日在联交所场内以每股均价23.4445港元买入劲方医药-B股份29.96万股，涉资约702.40万港元，属场内主动交易，即在二级市场直接买卖股份。东方证券股份有限公司（DFZQ）此次增持前持有劲方医药-B好仓1747.52万，占比4.96%；增持后持股量为1777.48万，好仓比例升至5.05%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104301203","title":"异动解读｜劲方医药-B盘中上涨5.05%，汇添富基金增持后持股比例升至5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104301203","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104301203?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:39","pubTimestamp":1793842792,"startTime":"0","endTime":"0","summary":"11月5日，劲方医药-B盘中上涨5.05%，报22.58港元，成交额733.58万港元。消息面上，汇添富基金于10月30日在联交所场内增持劲方医药-B29.96万股，每股作价23.4445港元，涉资约702.40万港元，增持后持股增至1777.48万股，持股比例由4.96%升至5.05%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药获汇添富增持，泛RAS管线进展受关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680903064","title":"汇添富基金增持劲方医药-B(02595)29.96万股 每股作价约23.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680903064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680903064?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:19","pubTimestamp":1793791162,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月30日，汇添富基金增持劲方医药-B(02595)29.96万股，每股作价23.4445港元，总金额约为702.40万港元。增持后最新持股数目为1777.48万股，持股比例为5.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","BK1515","02595","09939","BK1161","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148568927","title":"劲方医药-B：汇添富基金管理股份有限公司增持，好仓比例升至5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148568927","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148568927?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:15","pubTimestamp":1793783746,"startTime":"0","endTime":"0","summary":"汇添富基金管理股份有限公司于2026年10月30日在联交所场内以每股均价23.4445港元买入劲方医药-B（02595）股份29.96万股，涉资约702.40万港元，属场内主动交易，即在二级市场直接买卖股份。汇添富基金管理股份有限公司此次增持前持有劲方医药-B好仓1747.52万，占比4.96%；增持后持股量为1777.48万，好仓比例升至5.05%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164787648","title":"劲方医药-B更新10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1164787648","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164787648?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:02","pubTimestamp":1793782951,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司于2026年11月4日披露2026年10月股份变动月报表，报告期为2026年10月1日至10月31日。根据公告，相较上一月末，公司总股本数未发生变化，整体股本保持稳定。公司未上市普通股数量则维持32,337,610股不变，面值合计人民币3,233,761元。公司截至10月底的法定/注册股本合计约人民币38,396,663元，股本总数保持稳定。公司表示将严格遵守香港联交所《上市规则》及相关法律法规，持续完善公司治理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156035680","title":"异动解读｜劲方医药-B盘中上涨5.17%，GFH276多项联合疗法获临床许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1156035680","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156035680?lang=zh_cn&edition=full","pubTime":"2026-11-04 11:25","pubTimestamp":1793762706,"startTime":"0","endTime":"0","summary":"11月4日，劲方医药-B盘中上涨5.17%，报19.73港元，成交额3168.95万港元。消息面上，公司公告称，自第三季度以来，口服泛RAS抑制剂GFH276多项创新联合疗法已获国内临床试验许可，或完成澳大利亚临床试验备案，将在国内外开展一线及后线大适应症瘤种研究。劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司。该公司主要在中国国内和海外市场开展业务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药异动拉升，GFH276联合疗法获批临床","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680970277","title":"港股异动 | 劲方医药-B(02595)早盘涨近5% GFH276多项创新联合疗法获临床许可 将在国内外开展研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2680970277","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680970277?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:54","pubTimestamp":1793757296,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B早盘涨近5%。截至发稿，涨3.84%，报19.48港元，成交额1561.91万港元。消息面上，劲方医药发布公告，自今年第三季度以来，口服泛RAS抑制剂GFH276的多项创新联合疗法已获得国内CDE颁发的临床试验许可、或完成澳大利亚TGA临床试验备案。招商证券发布研报称，GFH276首次人体数据积极，PDAC 41%的ORR及14.8%的≥3级TRAE是核心亮点，早期疗效与安全性组合展现优于RMC-6236同期数据的潜力，具备全球pan-RAS抑制剂潜在BIC竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","BK1515","BK4585","VXUS","BK1161","02595","BK4588","KCAI","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680702771","title":"港股异动 | 劲方医药-B(02595.HK)早盘涨近5% GFH276多项创新联合疗法获临床许可 将在国内外开展研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2680702771","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680702771?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:54","pubTimestamp":1793757296,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1515","09939","BK1574","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680706244","title":"劲方医药-B(02595)：口服泛 RAS 抑制剂 GFH276 多项创新联合疗法近期获得临床试验许可， 在国内或海外开展一线及后线大适应症瘤种临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2680706244","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680706244?lang=zh_cn&edition=full","pubTime":"2026-11-04 07:37","pubTimestamp":1793749068,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，自今年第三季度以来，口服泛 RAS 抑制剂 GFH276 的多项创新联合疗法已获得国内 CDE 颁发的临床试验许可、或完成澳大利亚 TGA 临床试验备案 。相关研究涵盖多个 RAS 突变大适应症瘤种的一线及后线治疗 ，其中有试验已招募多个剂量水平患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","PSYK","IBBJ","MDTX","02595","BK1515","159938","IBBQ","09939","BMED","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680706228","title":"劲方医药-B(02595.HK)：口服泛 RAS 抑制剂 GFH276 多项创新联合疗法近期获得临床试验许可， 在国内或海外开展一线及后线大适应症瘤种临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2680706228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680706228?lang=zh_cn&edition=full","pubTime":"2026-11-04 07:37","pubTimestamp":1793749068,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1161","02595","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160528243","title":"劲方医药-B（02595）口服泛RAS抑制剂GFH276多项联合疗法获中澳临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1160528243","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160528243?lang=zh_cn&edition=full","pubTime":"2026-11-04 07:36","pubTimestamp":1793748978,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司11月4日公告称，自2026年第三季度以来，其口服泛RAS抑制剂GFH276的多项联合疗法先后获得国家药品监督管理局药品审评中心的临床试验许可，或已在澳大利亚完成治疗商品管理局的临床试验备案。相关研究覆盖多种RAS突变大适应症瘤种，布局一线及后线治疗。其中部分临床试验已完成多个剂量水平患者入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161626523","title":"劲方医药-B回购10.1万股股份，耗资约191.11万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161626523","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161626523?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:27","pubTimestamp":1793698025,"startTime":"0","endTime":"0","summary":"劲方医药科技(上海)股份有限公司于2026年11月3日公告称，公司在香港联交所场内回购股份，总数为101,000股，约占当日现有已发行股本的0.029%。本次回购的最高价为每股18.97港元，最低价为18.72港元，合计耗资1,911,094港元，折合约191.11万港元。公司回购授权于2026年5月11日获得通过，最多可回购股份37,036,663股，而截至目前已累计在香港联交所等进行回购的股份总数为2,687,800股，占授权通过当日发行股份总数的约0.726%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药-B回购10.1万股股份，耗资约191.11万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153202235","title":"劲方医药-B11月2日回购450,000股，耗资约933.98万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153202235","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153202235?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:37","pubTimestamp":1793612225,"startTime":"0","endTime":"0","summary":"劲方医药科技(上海)股份有限公司于2026年11月2日公告，已在香港联交所场内回购公司H股合计450,000股，约占回购前公司已发行股份349,492,220股的0.129%。本次回购价格介于每股20.56港元至21.06港元之间，总金额约9,339,812港元。公司表示，本次回购已获董事会正式授权，并遵守香港联合交易所有限公司证券上市规则及所有适用的法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药-B11月2日回购450,000股，耗资约933.98万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680730954","title":"劲方医药-B(02595.HK)11月2日斥资933.98万港元回购45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680730954","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680730954?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:34","pubTimestamp":1793612090,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02595","BK1515","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146205490","title":"异动解读｜劲方医药-B盘中下跌7.11%，连续回购后股价仍承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1146205490","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146205490?lang=zh_cn&edition=full","pubTime":"2026-11-02 14:53","pubTimestamp":1793602414,"startTime":"0","endTime":"0","summary":"11月2日，劲方医药-B盘中下跌7.11%，报20.9港元，成交额8641.1万港元。消息面上，公司近日连续实施回购，但二级市场抛压仍未明显缓解。10月30日公司斥资约1297.13万港元回购56万股，回购价为22.58港元至24.06港元；10月29日又回购26.5万股，耗资约670.34万港元。此前市场已有异动解读指出，连续回购规模相对总股本占比仍有限，未能扭转短线资金兑现压力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药连续回购，股价依旧承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120141594","title":"劲方医药-B：10月30日回购56万股股份，耗资约1,297.13万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120141594","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120141594?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:42","pubTimestamp":1793353378,"startTime":"0","endTime":"0","summary":"10月30日，劲方医药科技(上海)股份有限公司发布翌日披露报表，披露公司于2026年10月30日在香港联交所场内回购普通股56万股，占回购前公司已发行股份总数的约0.16%。本次回购价格介乎每股港币22.58元至24.06元，平均每股价格约为港币23.16元，合计耗资港币12,971,308元，折合约1,297.13万港元。公告显示，本次股份回购完成后，劲方医药-B已发行股份数量变动为349,492,220股，库藏股增加至2,136,800股，公司股份总数仍为351,629,020股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药-B：10月30日回购56万股股份，耗资约1,297.13万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679299163","title":"劲方医药-B(02595)10月30日斥资约1297.13万港元回购56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679299163","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679299163?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:38","pubTimestamp":1793353101,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年10月30日该公司斥资约1297.13万港元回购56万股，回购价格为每股22.58至24.06港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","02595","BK1515","159938","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126897690","title":"劲方医药-B：10月29日回购26.5万股，耗资约670.34万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126897690","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126897690?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:32","pubTimestamp":1793266342,"startTime":"0","endTime":"0","summary":"劲方医药科技(上海)股份有限公司于2026年10月29日向香港联交所提交翌日披露报表，公告当日于联交所场内回购普通股265,000股。该回购数量约占此前已发行股份总数0.076%，回购价格介乎每股24.68港元至26.08港元，总金额约670.34万港元。回购完成后，劲方医药-B已发行股份数量为350,052,220股，库藏股数量为1,576,800股，总股本351,629,020股。上述公告由劲方医药-B联席公司秘书张巍签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药-B：10月29日回购26.5万股，耗资约670.34万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfleet.com","stockEarnings":[{"period":"1week","weight":-0.0311},{"period":"1month","weight":-0.32},{"period":"3month","weight":-0.2709},{"period":"6month","weight":-0.4785},{"period":"1year","weight":-0.1944},{"period":"ytd","weight":-0.0833}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发，以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发，分子工艺路线和质量标准的研究，以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"劲方医药-B","nameEN":"GENFLEET-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"劲方医药-B,02595,劲方医药-B股票,劲方医药-B股票老虎,劲方医药-B股票老虎国际,劲方医药-B行情,劲方医药-B股票行情,劲方医药-B股价,劲方医药-B股市,劲方医药-B股票价格,劲方医药-B股票交易,劲方医药-B股票购买,劲方医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}